Prior to founding Hanne Capital in early 2017, Mr. Zhou has been an investment committee member and the partner in charge of healthcare practice at New Horizon Capital for 9 years. Under his leadership the team has made multiple landmark investments across all segments of healthcare industry. 

His representative portfolios include Zylox Ton-Bridge Medical (HK:02190), HiFiBio, Biotheus (NASDAQ:BNTX), EOC Pharma, BioNova, Rezubio, KYInno, Linkgel Medical, Innocare(SH: 688428), Microport Endovascular (SH: 688016), SinoMed (SH: 688108), ZaiLab (NASAQ: ZLAB), Scion Medtech (NYSE: VAR), Hile Bio-tech (SH: 603718)，HEC Changjiang Pharma (HK:1558) and Allgens Medical (SH: 688613). 

Mr. Zhou was a founding partner of Qiming Ventures before joining New Horizon in 2008. He led

Qiming’s angel investment in PPStream (NASDAQ:IQ). Early in his investment career Mr. Zhou was a strategic investment director at Cisco Systems where he was responsible for strategic investments, M&A as well as strategic partnerships in Asia Pacific region. In 2004 he led Cisco’s Series A investment in Alchip (TW: 3661). Mr. Zhou started his private equity investment career in 2003 and has been focusing on healthcare investments since 2010. 

Mr. Zhou holds an MBA degree from Kellogg School of Management, Northwestern University as well as bachelor’s and master’s degrees both from Shanghai Jiao Tong University. In October 2024 he was elected Executive Chairman of SJTU Alumni Association, Chapter for MedTech and Deputy Chairman of SJTU Alumni Association, Chapter for Biotech.